UY25824A1 - Antagonista del receptor de vitronectina - Google Patents
Antagonista del receptor de vitronectinaInfo
- Publication number
- UY25824A1 UY25824A1 UY25824A UY25824A UY25824A1 UY 25824 A1 UY25824 A1 UY 25824A1 UY 25824 A UY25824 A UY 25824A UY 25824 A UY25824 A UY 25824A UY 25824 A1 UY25824 A1 UY 25824A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compound
- treatment
- useful
- receptor antagonist
- vitronectin receptor
- Prior art date
Links
- 102100022337 Integrin alpha-V Human genes 0.000 title abstract 2
- 108010048673 Vitronectin Receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010012442 Dermatitis contact Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000010247 contact dermatitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describe un compuesto de la fórmula (I) que es un agente antagonista del receptor de vitronectina y es útil para el tratamiento de la osteoporosis: o una sal farmacéuticamente aceptable de éste. También es útil en el tratamiento de trastornos inflamatorios, cancerosos, cardiovasculares, tales como ateroesclerosis y reestenosis y enfermedades en las cuales la resorción del hueso constituye un factor. El compuesto de este invento puede ser útil para el tratamiento de heridas, rechazo de trasplantes, escema, dermatitis por contacto,etc. El compuesto de fórmula (I) se prepara según el esquema (I); Este invento proporciona un método para inhibir el tratamiento de tumores,que comprende administrar escanoladamente una combinación física de un compuesto (I) y un agente antineoplrsico
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11090398P | 1998-12-04 | 1998-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25824A1 true UY25824A1 (es) | 2001-07-31 |
Family
ID=22335565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25824A UY25824A1 (es) | 1998-12-04 | 1999-11-29 | Antagonista del receptor de vitronectina |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US6495560B1 (es) |
| EP (1) | EP1146874B1 (es) |
| JP (1) | JP4481504B2 (es) |
| KR (1) | KR100620485B1 (es) |
| CN (1) | CN1147300C (es) |
| AP (1) | AP1534A (es) |
| AR (1) | AR035006A1 (es) |
| AT (1) | ATE277043T1 (es) |
| AU (1) | AU754408B2 (es) |
| BG (1) | BG65118B1 (es) |
| BR (1) | BR9915879A (es) |
| CA (1) | CA2353415A1 (es) |
| CO (1) | CO5150166A1 (es) |
| CZ (1) | CZ20011963A3 (es) |
| DE (1) | DE69920518T2 (es) |
| DK (1) | DK1146874T3 (es) |
| DZ (1) | DZ2954A1 (es) |
| EA (1) | EA003254B1 (es) |
| EG (1) | EG24025A (es) |
| ES (1) | ES2229798T3 (es) |
| HK (1) | HK1042037B (es) |
| HU (1) | HUP0104804A3 (es) |
| ID (1) | ID28811A (es) |
| IL (2) | IL143390A0 (es) |
| MA (1) | MA25265A1 (es) |
| NO (1) | NO318895B1 (es) |
| NZ (1) | NZ511876A (es) |
| OA (1) | OA11724A (es) |
| PE (1) | PE20001563A1 (es) |
| PL (1) | PL195973B1 (es) |
| PT (1) | PT1146874E (es) |
| SI (1) | SI1146874T1 (es) |
| SK (1) | SK7452001A3 (es) |
| TR (1) | TR200101654T2 (es) |
| TW (1) | TW482673B (es) |
| UA (1) | UA71586C2 (es) |
| UY (1) | UY25824A1 (es) |
| WO (1) | WO2000033838A1 (es) |
| ZA (1) | ZA200104398B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020665A1 (es) | 2000-06-15 | 2002-08-14 | Pharmacia Corp | ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3 |
| JP2004513953A (ja) * | 2000-10-24 | 2004-05-13 | メルク エンド カムパニー インコーポレーテッド | ジベンズオキサゼピンαＶインテグリン受容体アンタゴニスト |
| ATE530183T1 (de) | 2001-01-29 | 2011-11-15 | Ortho Mcneil Pharm Inc | Substituierte indole und ihre verwendung als integrin-antagonisten |
| US6872730B2 (en) * | 2001-04-27 | 2005-03-29 | 3-Dimensional Pharmaceuticals, Inc. | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| AU2003297408A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Thiazole compounds as integrin receptor antagonists derivatives |
| GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| JP2008524334A (ja) * | 2004-12-21 | 2008-07-10 | スミスクライン・ビーチャム・コーポレイション | 方法および処方 |
| PH12013500084A1 (en) | 2010-07-14 | 2015-09-11 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
| UY34572A (es) | 2012-01-13 | 2013-09-02 | Novartis Ag | Compuestos heterocíclicos agonistas del receptor ip |
| CN105189500A (zh) | 2013-02-13 | 2015-12-23 | 诺华股份有限公司 | Ip受体激动剂杂环化合物 |
| EP3929196B1 (en) | 2013-09-24 | 2023-08-23 | FUJIFILM Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2687154B1 (fr) * | 1992-02-07 | 1995-05-12 | Rhone Poulenc Rorer Sa | Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent. |
| WO1997001540A1 (en) * | 1995-06-29 | 1997-01-16 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| WO1998013278A1 (de) * | 1996-09-27 | 1998-04-02 | Merkler, H. | Tank für flüssigkeiten, insbesondere für chemisch aggressive flüssigkeiten |
| JP2001501951A (ja) | 1996-10-07 | 2001-02-13 | スミスクライン・ビーチャム・コーポレイション | 骨形成刺激方法 |
| UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
-
1999
- 1999-03-12 UA UA2001063754A patent/UA71586C2/uk unknown
- 1999-11-29 TW TW088120752A patent/TW482673B/zh not_active IP Right Cessation
- 1999-11-29 UY UY25824A patent/UY25824A1/es unknown
- 1999-11-30 PE PE1999001197A patent/PE20001563A1/es not_active Application Discontinuation
- 1999-11-30 CO CO99075061A patent/CO5150166A1/es unknown
- 1999-12-01 DZ DZ990254A patent/DZ2954A1/xx active
- 1999-12-02 EG EG154299A patent/EG24025A/xx active
- 1999-12-02 AR ARP990106128A patent/AR035006A1/es unknown
- 1999-12-03 JP JP2000586330A patent/JP4481504B2/ja not_active Expired - Fee Related
- 1999-12-03 CN CNB998159735A patent/CN1147300C/zh not_active Expired - Fee Related
- 1999-12-03 TR TR2001/01654T patent/TR200101654T2/xx unknown
- 1999-12-03 AU AU17502/00A patent/AU754408B2/en not_active Ceased
- 1999-12-03 PL PL99348702A patent/PL195973B1/pl not_active IP Right Cessation
- 1999-12-03 ES ES99960647T patent/ES2229798T3/es not_active Expired - Lifetime
- 1999-12-03 EP EP99960647A patent/EP1146874B1/en not_active Expired - Lifetime
- 1999-12-03 SI SI9930700T patent/SI1146874T1/xx unknown
- 1999-12-03 KR KR1020017006937A patent/KR100620485B1/ko not_active Expired - Fee Related
- 1999-12-03 NZ NZ511876A patent/NZ511876A/xx unknown
- 1999-12-03 AT AT99960647T patent/ATE277043T1/de not_active IP Right Cessation
- 1999-12-03 HK HK02101522.3A patent/HK1042037B/en not_active IP Right Cessation
- 1999-12-03 ID IDW00200101183A patent/ID28811A/id unknown
- 1999-12-03 IL IL14339099A patent/IL143390A0/xx active IP Right Grant
- 1999-12-03 EA EA200100618A patent/EA003254B1/ru not_active IP Right Cessation
- 1999-12-03 WO PCT/US1999/028662 patent/WO2000033838A1/en not_active Ceased
- 1999-12-03 SK SK745-2001A patent/SK7452001A3/sk unknown
- 1999-12-03 DE DE69920518T patent/DE69920518T2/de not_active Expired - Lifetime
- 1999-12-03 PT PT99960647T patent/PT1146874E/pt unknown
- 1999-12-03 AP APAP/P/2001/002156A patent/AP1534A/en active
- 1999-12-03 HU HU0104804A patent/HUP0104804A3/hu unknown
- 1999-12-03 CA CA002353415A patent/CA2353415A1/en not_active Abandoned
- 1999-12-03 BR BR9915879-5A patent/BR9915879A/pt not_active Application Discontinuation
- 1999-12-03 DK DK99960647T patent/DK1146874T3/da active
- 1999-12-03 US US09/857,316 patent/US6495560B1/en not_active Expired - Lifetime
- 1999-12-03 CZ CZ20011963A patent/CZ20011963A3/cs unknown
- 1999-12-03 OA OA1200100139A patent/OA11724A/en unknown
-
2001
- 2001-05-24 IL IL143390A patent/IL143390A/en not_active IP Right Cessation
- 2001-05-29 ZA ZA200104398A patent/ZA200104398B/en unknown
- 2001-06-01 NO NO20012732A patent/NO318895B1/no not_active IP Right Cessation
- 2001-06-01 MA MA26218A patent/MA25265A1/fr unknown
- 2001-06-26 BG BG105651A patent/BG65118B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE249214T1 (de) | Pentafluorobenzensulfonamide und analoge | |
| UY25824A1 (es) | Antagonista del receptor de vitronectina | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| AR029634A1 (es) | Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento | |
| PT1115701E (pt) | Ureias de arilsulfonanilida | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| CY1107853T1 (el) | Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων | |
| DK1438052T3 (da) | Quinazolin-4-oner af inhibitorer som human phosphatidylinositol 3-kinase delta | |
| ATE444960T1 (de) | Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer | |
| ATE453636T1 (de) | Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren | |
| DE60329073D1 (de) | Edg-rezeptoragonisten | |
| BRPI0416692A (pt) | inibidores heterocìclicos de mek e métodos de emprego destes | |
| CY1108105T1 (el) | Ιβανδρονικο οξυ για την θεραπευτικη αντιμετωπιση και την προληψη της οστεoπορωσης | |
| BR0212251A (pt) | Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica, método para o tratamento preventivo e/ou terapêutico de uma doença ou distúrbio decorrente de proliferação celular anormal ou imprópria, e, uso do dito composto ou de um sal farmaceuticamente aceitável do mesmo | |
| ATE388708T1 (de) | Piperazinderivate und anwendungsverfahren | |
| AR044200A1 (es) | Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo | |
| CO5611124A2 (es) | Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos | |
| IL153147A0 (en) | Phospholipid derivatives of valporic acid and mixtures thereof | |
| DK1641454T3 (da) | Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere | |
| DK1284952T3 (da) | Substituerede chalconer som terapeutiske kompositioner | |
| SA523440403B1 (ar) | Magl مثبط | |
| GB9809349D0 (en) | Heterocyclic derivatives | |
| CL2008002480A1 (es) | Compuestos derivados de 3-(4-aminofenil)-metil-4-hidroxi-5-amino-tiopirano, inhibidores de beta-secretasa bace; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica, y su uso en el tratamiento de trastornos neurologicos o vaaculares, tal como la enfermedad de alzheimer, sindrome de down y deterioro de la memoria. | |
| BR0105775A (pt) | Compostos de n-benzenossulfonil-l-prolina como antagonistas da bradiquinina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ABAN | Application deemed to be withdrawn (no publication fee paid) |
Effective date: 20090416 |